Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of GME751 vs Keytruda in Stage II and III Melanoma
NCT06153238Phase 1Completed
- Sponsor
- Sandoz
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 1, randomised, double-blind trial of GME751 in melanoma (3 arms), sponsored by Sandoz. Primary endpoints: Area Under the Serum Concentration-time Curve from Time Zero to 42 Days and Area Under the Serum Concentration-time Curve Over the Dosing Interval at Steady State. Started May 2024; status: completed.
02
Drugs
GME751
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06153238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153238.